Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosena Therapeutics

- PMLiVE

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

- PMLiVE

GSK found UK’s drug pricing changes a tough sell

Firm's chief executive met with the government to question the last PPRS update

- PMLiVE

GSK to establish US R&D centre for vaccines

Facility will be based in Rockville, Maryland

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

- PMLiVE

Pricing pressures preventing UK access to MenB vaccine

GlaxoSmithKline’s Bexsero will need a dramatic price cut to gain NHS entry

- PMLiVE

FDA panel backs GSK’s asthma drug Breo for adults only

Already approved to treat COPD in the US

- PMLiVE

GSK: We had a social responsibility to work on Ebola

And company says it delayed more commercialprojects to do so

- PMLiVE

GSK and Lilly invest in $100m global Dementia Discovery Fund

Fund announced at WHO conference by UK health secretary Jeremy Hunt

- PMLiVE

GSK sells another chunk of South Africa’s Aspen

Paid $418m for an 18% share in Aspen in 2009

Choices, choices: the rapidly evolving HIV treatment landscape

The treatment options for HIV in Europe has seen some revolutionary changes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links